Discovering Potential Genes and New Drugs in Alzheimer’s Disease：An in silico Approach
- VernacularTitle: 阿尔茨海默病的组学机制分析及药物预测
- Author:
Zhuoya WANG
1
;
Yanlin WANG
1
;
Zhihua YANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Alzheimer’s disease ； Bioinformatics ； Genes ； Drugs
- From: Journal of Apoplexy and Nervous Diseases 2021;38(9):804-809
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate differential expression genes （DEGs） between Alzheimer’s disease （AD） and normal controls by bioinformatics analysis.Methods The microarray dataset GSE5281 was download from GEO database，which included brain tissue in AD and normal controls. The DEGs were obtained by R project.Analysis of DEGs based in DAVID database was used to obtain gene ontology（GO）and kyoto encyclopedia of genes and genomes （KEGG） pathway.The protein protein interaction network （PPI） was established using STRING database to identify hub genes. and core genes.Moreover，the existing drugs target to these core genes were screen to explore the therapeutic effect for AD.Results A total 863 DEGs were obtained，of which 246 genes were up-regulated and 617 genes were down-regulated in AD group.GO showed that DEGs were mainly involved in ATP binding，and KEGG pathway involved several neurodegenerative diseases including Parkinson’s disease and prion disease，long-term potentiation and axon guidance.5 core genes（PSMA7，PSMA3，PSMB7，PSMC5 and PSMC3） and 31 hub genes including 23 up regulated genes and 8 down-regulated genes were obtained by PPI analysis.Several existing drugs have targeted to core genes. Some common differential expression genes were obtained by paired comparison of 3 groups of gene microarrays.Conclusion Bioinformatics analysis based on GEO database showed that there were DEGs between Alzheimer’s disease（AD）and normal controls，and 8 existing drugs were identified.
- Full text:2024072910195874821阿尔茨海默病的组学机制分析及药物预测.pdf
